「Merck」の共起表現一覧(1語右で並び替え)
該当件数 : 84件
| and is now the president of | Merck's Vaccine division.She is also Director of MSD |
| The new joint venture will be equally owned by | Merck and sanofi-aventis. |
| er several brand names, most notably Tinactin ( | Merck) and Odor Eaters (Combe Incorporated). |
| op four being GlaxoSmithKline, Sanofi-Aventis, | Merck and Novartis. |
| In March, 2007, | Merck and H. Lundbeck cancelled work on the drug, ci |
| by Merial Animal Health, Mectizan in Canada by | Merck and Ivexterm in Mexico by Valeant Pharmaceutic |
| On February 18, 2008, Takeda and | Merck announced that they would no longer pursue the |
| Wallace | Merck as Hunter #3 |
| y been commercially available since 2001, when | Merck began their Chromolith campaign. |
| Merck, born in Hamburg, was a member of the Frankfur | |
| It was patented as an anticonvulsant by | Merck but was never marketed. |
| mstadt had a few industrial targets of note, a | Merck chemical factory being one of them. |
| sly served as president of Johnson & Johnson - | Merck Consumer Pharmaceuticals since 1999. |
| Dupont purchased | Merck's share in the joint venture in 1998 and began |
| ntelukast stands for Montreal, the place where | Merck developed the drug. |
| Merck distinguished himself mainly as a critic; his | |
| In 1951, | Merck donated 3100 acres of forest and farmland to b |
| He worked at | Merck, DuPont-Merck, and Bristol-Myers Squibb. |
| for Gulf Oil in Pittsburgh, he was director of | Merck Finck & Co and LGT Bank. |
| After his death, the area was renamed the | Merck Forest and Farmland Foundation which seeks to |
| (Roberts), Myotonachol (Glenwood), Urecholine ( | Merck Frosst) and Urocarb (Hamilton). |
| ocarpine (Schein Pharmaceutical), and Timpilo ( | Merck Frosst). |
| Then on the 30th of September | Merck gave out a news release announcing their volun |
| He consulted extensively with Exxon, | Merck, Goodyear, General Electric, and Nestle and al |
| GTx and | Merck had clinical development plans to evaluate Ost |
| In October 2008, | Merck has stopped its phase III clinical trials with |
| Schering-Plough and | Merck have sought permission to market a combined ta |
| Following his departure from | Merck, Hirschammn taught at the University of Pennsy |
| Choi resigned from his position at | Merck in 2006. |
| ng-Plough in 2007; Schering-Plough merged with | Merck in 2009. |
| ion has been bought for further development by | Merck in April 2009. |
| While CEO of | Merck in 2008, Richard T. Clark earned a total compe |
| Joining | Merck in 1980, Lewent pioneered a new planning model |
| (developed by Dr. Cash and Dr. David Nalin (at | Merck in Vaccine Development from 1983 to 2002), Dr. |
| Mr Clark's previous leadership positions at | Merck include CEO (2005-2010), President (2005-2009) |
| The | Merck Index reports 122-125 Celsius. |
| The | Merck Index reports 155-156 Celsius. |
| The | Merck Index is an encyclopedia of chemicals, drugs a |
| The | Merck Index is also available by subscription in an |
| Merck Index, 11th Edition, 9857. | |
| of the most well-known references such as the | Merck Index, the CRC Handbook of Chemistry and Physi |
| The | Merck Index. |
| The | Merck Index: An Encyclopedia of Chemicals, Drugs, an |
| Emylcamate (marketed as Striatran by | Merck) is an anxiolytic and muscle relaxant. |
| BMS-345541, marketed by | Merck, is an anti-inflammatory, cell-permeable quino |
| has facilities in Ware and nearby Harlow, and | Merck is based at Gilston on the seat's southern bor |
| controller comarketed by Johnson & Johnson and | Merck, is a combination of the H2-blocker famotidine |
| Merck KGaA is the registered trademark owner of IR35 | |
| n Grimsby and Seven Seas Health Care (owned by | Merck KGaA) on Hedon Road in Hull. |
| ts partners are Eli Lilly, Novartis, Dendreon, | Merck KGaA, Solvay Pharmaceuticals , Bayer, etc. |
| It was directed by Zach | Merck, known for his previous work with Shadows Fall |
| assanutten Mountain range to the west, and the | Merck manufacturing plant and MillerCoors brewery an |
| President and Chief Financial Officer (CFO) of | Merck, one of the largest pharmaceutical companies i |
| Merck performed a dose-ranging study of anacetrapib, | |
| Richard T. Clark is the Chairman of | Merck Pharmaceutical Company, a position held since |
| was taken over by a new joint venture, Dupont | Merck Pharmaceutical Company. |
| t Central Research & Development (later DuPont | Merck Pharmaceutical Company). |
| In 1990, he joined DuPont | Merck Pharmaceutical Company where he was a Senior R |
| development by researchers and clinicians at: | Merck Pharmaceutical, Johnson & Johnson Pharmaceutic |
| Huawei, IKEA, Jollibee, Mead Johnson, Mengniu, | Merck, Pizza Hut, Proton, Remy Martin, Shanghai Gene |
| Merck Process Award (2008) | |
| e users include Johnson & Johnson, SC Johnson, | Merck, Raytheon and the U.S. Securities and Exchange |
| ng Lipid Metabolism (New York, Oct 4-7, 2007), | Merck reported on a Phase IIb study. |
| The award was established in 1988 by | Merck Research Laboratories. |
| Merck Research Laboratories Boston, Boston, Massachu | |
| of 2001 he left the full-time faculty to join | Merck Research Labs. |
| Efalizumab (trade name Raptiva, Genentech, | Merck Serono) is a medication designed to treat psor |
| As government affairs adviser to | Merck Sharp and Dohme Australia, she assisted in obt |
| From 1994 to 1996 he was working for | Merck Sharp and Dohme, (MSD), as a health outcome ma |
| ic drug invented in 2004 by a team working for | Merck, Sharp and Dohme, which acts as a subtype-sele |
| L-733,060 is a drug developed by | Merck, Sharpe & Dohme which acts as an orally active |
| Lieutenant in US Army (1970-1972) employed by | Merck since 1972. |
| Merck started a Phase III trial to assess the drug's | |
| and 07 Aug 2007, Lewent sold 200,000 shares of | Merck stock for about $10,262,000, according to Secu |
| Merck stopped the trial on what was considered a ver | |
| Starting in late 2009 and continuing into 2011 | Merck stopped manufacturing the drug while awaiting |
| e reasons he decided to switch from his job at | Merck to M.I.T. was because “At M.I.T, I was a resea |
| His first research assignment at | Merck was to develop an economical process for produ |
| In 1853 | Merck was appointed as consul for Austria in Hamburg |
| Merck was on the cover of Time magazine on August 18 | |
| Merck was also the cavalry chief of the Hamburg Citi | |
| This drug, developed by | Merck, was the first drug in human therapy (market i |
| tical industry stalwarts, including Pfizer and | Merck, with his discovery, but they declined. |
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|